AIP
NBRV

Almanack Investment Partners’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Almanack Investment Partners’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,629
Closed -$1.63M – 205
2017
Q2 		$1.63M Buy
3,629
+3,006
+483% +$7.75M 0.91% 33
2017
Q1 		$1.87M Buy
+623
New +$1.51M 1.4% 23

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Almanack Investment Partners's NBRV Position: Q3 2017 in Review

Almanack Investment Partners sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2017, closing a stake of 3,629 shares — an estimated $1.63M sold.

Almanack Investment Partners first reported a position in NBRV in Q1 2017 and held it in 2 quarters. The position peaked at $1.87M in Q1 2017. 41 funds tracked by Wall St. Rank hold NBRV as of Q3 2017.

  • Almanack Investment Partners reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2017 after selling out during the quarter.
  • Almanack Investment Partners sold 3,629 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2017, an estimated $1.63M.
  • Almanack Investment Partners first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2017 and held it in 2 quarters.
  • Almanack Investment Partners's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $1.87M in Q1 2017.
  • 41 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2017.

Based on Almanack Investment Partners's 13F filing for Q3 2017, filed 13 Nov 2017.